You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameOmeprazole
Accession NumberDB00338  (APRD00446)
TypeSmall Molecule
GroupsApproved, Investigational, Vet Approved
DescriptionA highly effective inhibitor of gastric acid secretion used in the therapy of stomach ulcers and Zollinger-Ellison syndrome. Omeprazole belongs to a class of antisecretory compounds, the substituted benzimidazoles, that suppress gastric acid secretion by specific inhibition of the H+/K+ ATPase enzyme system at the secretory surface of the gastric parietal cell.
Structure
Thumb
Synonyms
OMEP
OMP
OMZ
Prilosec
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-omeprazoleCapsule, delayed release10 mgOralAuro Pharma Inc2014-03-26Not applicableCanada
Auro-omeprazoleCapsule, delayed release20 mgOralAuro Pharma Inc2014-03-26Not applicableCanada
Ava-omeprazoleCapsule, delayed release20 mgOralAvanstra Inc2011-11-282014-08-21Canada
Bio-omeprazoleTablet, delayed release20 mgOralBiomed Pharma2016-09-07Not applicableCanada
Dom-omeprazole DrTablet, delayed release10 mgOralDominion PharmacalNot applicableNot applicableCanada
Dom-omeprazole DrTablet, delayed release20 mgOralDominion Pharmacal2013-01-23Not applicableCanada
Jamp-omeprazole DrTablet, delayed release20 mgOralJamp Pharma Corporation2014-02-11Not applicableCanada
Leader OmeprazoleTablet, delayed release20 mg/1OralREMEDYREPACK INC.2013-06-04Not applicableUs
Losec 10 mgTablet, delayed release10 mgOralAstrazeneca Canada Inc1997-04-28Not applicableCanada
Losec 20 mgTablet, delayed release20 mgOralAstrazeneca Canada Inc1996-12-31Not applicableCanada
Losec Capsules 10mgCapsule, delayed release10 mgOralAstrazeneca Canada Inc2000-10-032013-12-04Canada
Losec Capsules 20mgCapsule, delayed release20 mgOralAstrazeneca Canada Inc1989-12-31Not applicableCanada
Losec Capsules 40mgCapsule, delayed release40 mgOralAstrazeneca Canada Inc2003-10-172010-06-30Canada
Losec Mups - 10mgTablet, delayed release10 mgOralAstrazeneca Canada Inc2001-02-222009-12-01Canada
Losec Mups - 20mgTablet, delayed release20 mgOralAstrazeneca Canada Inc2001-02-222009-12-01Canada
Mylan-omeprazoleCapsule, delayed release10 mgOralMylan Pharmaceuticals Ulc2009-08-04Not applicableCanada
Mylan-omeprazoleCapsule, delayed release20 mgOralMylan Pharmaceuticals Ulc2009-08-04Not applicableCanada
Nat-omeprazole DrTablet, delayed release20 mgOralNatco Pharma (Canada) Inc2015-07-22Not applicableCanada
OmeprazoleCapsule, delayed release20 mgOralSivem Pharmaceuticals Ulc2012-06-10Not applicableCanada
OmeprazoleCapsule, delayed release10 mgOralSivem Pharmaceuticals UlcNot applicableNot applicableCanada
OmeprazoleTablet, delayed release20 mg/1OralREMEDYREPACK INC.2013-06-06Not applicableUs
OmeprazoleCapsule, delayed release20 mgOralPro Doc Limitee2010-02-05Not applicableCanada
OmeprazoleCapsule, delayed release20 mgOralSanis Health Inc2010-06-16Not applicableCanada
Omeprazole Delayed-releaseCapsule, delayed release40 mg/1OralRanbaxy Laboratories Inc.2008-07-25Not applicableUs
Omeprazole Magnesium Delayed Release TabletsTablet, delayed release20 mgOralAccord Healthcare Inc2013-12-05Not applicableCanada
Omeprazole Magnesium Delayed Release TabletsTablet, delayed release20 mgOralDr Reddys Laboratories LtdNot applicableNot applicableCanada
Omeprazole-20Capsule, delayed release20 mgOralSivem Pharmaceuticals Ulc2013-10-23Not applicableCanada
PMS-omeprazoleCapsule, delayed release10 mgOralPharmascience IncNot applicableNot applicableCanada
PMS-omeprazoleCapsule, delayed release20 mgOralPharmascience Inc2009-03-13Not applicableCanada
PMS-omeprazole DrTablet, delayed release10 mgOralPharmascience Inc2009-01-08Not applicableCanada
PMS-omeprazole DrTablet, delayed release20 mgOralPharmascience Inc2009-01-08Not applicableCanada
PrilosecCapsule20 mg/1OralSTAT Rx USA LLC2009-09-30Not applicableUs
PrilosecGranule, delayed release2.5 mg/1OralAstra Zeneca Pharmaceuticals Lp2002-02-09Not applicableUs
PrilosecCapsule, delayed release20 mg/1OralAstra Zeneca Pharmaceuticals Lp1990-10-01Not applicableUs
PrilosecCapsule, delayed release10 mg/1OralAstra Zeneca Pharmaceuticals Lp1995-11-15Not applicableUs
PrilosecCapsule, delayed release40 mg/1OralAstra Zeneca Pharmaceuticals Lp1998-06-08Not applicableUs
PrilosecGranule, delayed release10 mg/1OralAstra Zeneca Pharmaceuticals Lp2002-02-09Not applicableUs
Priva-omeprazoleTablet, delayed release20 mgOralPharmapar Inc2016-09-07Not applicableCanada
Q-omeprazoleCapsule, delayed release10 mgOralQd Pharmaceuticals UlcNot applicableNot applicableCanada
Q-omeprazoleCapsule, delayed release20 mgOralQd Pharmaceuticals Ulc2012-02-032015-08-21Canada
Ran-omeprazoleTablet, delayed release20 mgOralRanbaxy Pharmaceuticals Canada Inc.2011-11-29Not applicableCanada
Ran-omeprazoleCapsule, delayed release20 mgOralRanbaxy Pharmaceuticals Canada Inc.2013-06-12Not applicableCanada
Ratio-omeprazoleTablet, delayed release20 mgOralTeva Canada Limited2005-01-24Not applicableCanada
Ratio-omeprazoleTablet, delayed release10 mgOralTeva Canada Limited2005-01-24Not applicableCanada
Riva-omeprazole DrTablet, delayed release20 mgOralLaboratoire Riva Inc2013-07-25Not applicableCanada
Sandoz OmeprazoleCapsule, delayed release20 mgOralSandoz Canada Incorporated2007-09-14Not applicableCanada
Sandoz OmeprazoleTablet, delayed release10 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Sandoz OmeprazoleCapsule, delayed release10 mgOralSandoz Canada Incorporated2007-09-14Not applicableCanada
Sandoz OmeprazoleTablet, delayed release20 mgOralSandoz Canada IncorporatedNot applicableNot applicableCanada
Teva-omeprazoleTablet, delayed release10 mgOralTeva Canada Limited2008-09-02Not applicableCanada
Teva-omeprazoleTablet, delayed release20 mgOralTeva Canada Limited2008-09-02Not applicableCanada
Van-omeprazoleTablet, delayed release20 mgOralVanc Pharmaceuticals Inc2015-06-22Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-omeprazoleCapsule, delayed release20 mgOralApotex Inc2004-01-28Not applicableCanada
Apo-omeprazoleCapsule, delayed release40 mgOralApotex IncNot applicableNot applicableCanada
OmeprazoleCapsule10 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-12Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralApotex Corp2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralRx Change Co.2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralAltura Pharmaceuticals, Inc.2010-01-01Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralDr. Reddy's Laboratories Limited2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralPhysicians Total Care, Inc.2003-09-03Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralKremers Urban Pharmaceuticals Inc.2002-11-04Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralSandoz Inc2003-01-28Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralUnit Dose Services2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralZydus Pharmaceuticals (USA) Inc.2012-11-23Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralPd Rx Pharmaceuticals, Inc.2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralCitron Pharma LLC2015-08-19Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralRebel Distributors Corp.2003-09-03Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralProficient Rx LP2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release pellets20 mg/1OralContract Pharmacy Services Pa2010-03-09Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralMc Kesson Contract Packaging2003-01-28Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralNorthwind Pharmaceuticals, LLC2015-02-05Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralREMEDYREPACK INC.2013-01-03Not applicableUs
OmeprazoleCapsule, delayed release pellets40 mg/1OralKAISER FOUNDATION HOSPITALS2009-08-01Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralA S Medication Solutions2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralPreferred Pharmaceuticals Inc2015-05-08Not applicableUs
OmeprazoleCapsule, delayed release pellets10 mg/1OralActavis Pharma, Inc.2008-07-25Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralRebel Distributors Corp2007-10-22Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralCadila Healthcare Limited2012-11-23Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-10Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralCarilion Materials Management2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralCardinal Health2011-01-14Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralA S Medication Solutions2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralBlenheim Pharmacal, Inc.2013-09-30Not applicableUs
OmeprazoleCapsule40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-13Not applicableUs
OmeprazoleCapsule40 mg/1OralUnit Dose Services2010-10-13Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralREMEDYREPACK INC.2013-03-062016-12-01Us
OmeprazoleCapsule, delayed release20 mg/1OralGolden State Medical Supply2013-03-22Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralAidarex Pharmaceuticals LLC2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1Oralbryant ranch prepack2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralAmerican Health Packaging2013-07-02Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralBlenheim Pharmacal, Inc.2016-02-09Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralState of Florida DOH Central Pharmacy2014-01-01Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralClinical Solutions Wholesale2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-22Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralAurobindo Pharma Limited2015-08-19Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralZydus Pharmaceuticals (USA) Inc.2012-11-23Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralAv Pak2011-07-11Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralApotex Corp2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2012-04-03Not applicableUs
OmeprazoleCapsule, delayed release pellets20 mg/1OralReady Meds2008-07-25Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralLegacy Pharmaceutical Packaging2012-02-07Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralDr. Reddy's Laboratories Limited2014-03-01Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralCardinal Health2010-05-04Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralKremers Urban Pharmaceuticals Inc.2009-01-23Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralMajor Pharmaceuticals2008-02-28Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralKAISER FOUNDATION HOSPITALS2006-06-02Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralREMEDYREPACK INC.2016-07-07Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralMylan Pharmaceuticals Inc.2003-08-04Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralAphena Pharma Solutions Tennessee, Llc2009-01-23Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralCitron Pharma LLC2015-08-19Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralRebel Distributors Corp.2002-11-04Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralProficient Rx LP2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralAphena Pharma Solutions Tennessee, Llc2002-11-04Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralREMEDYREPACK INC.2016-01-06Not applicableUs
OmeprazoleCapsule, delayed release pellets10 mg/1OralREMEDYREPACK INC.2013-02-112016-04-05Us
OmeprazoleCapsule, delayed release20 mg/1OralREMEDYREPACK INC.Not applicableNot applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralUnit Dose Services2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release pellets20 mg/1OralActavis Pharma, Inc.2008-07-25Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralSTAT Rx USA LLC2010-04-29Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralCadila Healthcare Limited2012-11-23Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralMidwest Drug Distribution, Inc.2015-02-04Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralSandoz Inc2003-01-28Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralCardinal Health2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralA S Medication Solutions2012-11-23Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralBlenheim Pharmacal, Inc.2014-10-15Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralA S Medication Solutions2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release pellets40 mg/1OralREMEDYREPACK INC.2013-02-152016-04-05Us
OmeprazoleCapsule, delayed release40 mg/1OralGolden State Medical Supply2013-03-22Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralAidarex Pharmaceuticals LLC2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2002-11-04Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralDr. Reddy's Laboratories Limited2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralPhysicians Total Care, Inc.2002-11-04Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralREMEDYREPACK INC.2015-05-20Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-01-28Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralPreferred Pharmaceuticals Inc.2016-09-29Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralAurobindo Pharma Limited2015-08-19Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralCardinal Health2008-02-28Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralMajor Pharmaceuticals2010-07-16Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralZydus Pharmaceuticals (USA) Inc.2012-11-23Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralAv Pak2011-07-11Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralApotex Corp2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2011-01-14Not applicableUs
OmeprazoleCapsule, delayed release pellets40 mg/1OralReady Meds2008-07-25Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralLegacy Pharmaceutical Packaging2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralDr. Reddy's Laboratories Limited2014-03-01Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralH.J. Harkins Company, Inc.2011-01-14Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralCardinal Health2009-12-07Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2003-01-28Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralMylan Pharmaceuticals Inc.2009-01-22Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralMedsource Pharmaceuticals2008-12-17Not applicableUs
OmeprazoleCapsule20 mg/1OralNew Horizon Rx Group, LLC2013-12-31Not applicableUs
OmeprazoleCapsule40 mg/1OralRebel Distributors Corp2010-10-13Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralProficient Rx LP2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralAmerican Health Packaging2009-12-07Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralMylan Institutional Inc.2003-09-01Not applicableUs
OmeprazoleCapsule, delayed release pellets40 mg/1OralActavis Pharma, Inc.2008-07-25Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralSTAT Rx USA LLC2009-04-17Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralCadila Healthcare Limited2012-11-23Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralAvera Mc Kennan Hospital2015-03-01Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralSandoz Inc2003-01-28Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralPd Rx Pharmaceuticals, Inc.2002-11-04Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralUnit Dose Services2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralBlenheim Pharmacal, Inc.2015-02-25Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralA S Medication Solutions2014-10-31Not applicableUs
OmeprazoleCapsule20 mg/1OralLake Erie Medical DBA Quality Care Products LLC2010-10-13Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralApotex Corp2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralAidarex Pharmaceuticals LLC2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2009-01-23Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralDr. Reddy's Laboratories Limited2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralPhysicians Total Care, Inc.2009-01-23Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralKremers Urban Pharmaceuticals Inc.2003-09-03Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralSandoz Inc2003-01-28Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralUnit Dose Services2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralAurobindo Pharma Limited2015-08-19Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralPreferred Pharmaceuticals, Inc.2012-01-10Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralDr. Reddy's Laboratories Limited2014-03-01Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralCardinal Health2003-01-282016-03-15Us
OmeprazoleCapsule, delayed release20 mg/1OralA S Medication Solutions2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralBlenheim Pharmacal, Inc.2013-09-30Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralLake Erie Medical DBA Quality Care Products LLC2014-03-01Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralPd Rx Pharmaceuticals, Inc.2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralUnit Dose Services2002-11-04Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralSt Marys Medical Park Pharmacy2013-08-08Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralRebel Distributors Corp2007-10-22Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralTYA Pharmaceuticals2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1Oralbryant ranch prepack2011-05-06Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralAmerican Health Packaging2009-12-07Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralClinical Solutions Wholesale2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralNcs Health Care Of Ky, Inc Dba Vangard Labs2007-10-22Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralGlenmark Pharmaceuticals Inc., Usa2014-10-31Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralMylan Pharmaceuticals Inc.2003-08-04Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralSafecor Health, LLC2014-09-30Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralGolden State Medical Supply, Inc2015-01-06Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralREMEDYREPACK INC.2013-04-222016-11-04Us
OmeprazoleCapsule, delayed release10 mg/1OralProficient Rx LP2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralPd Rx Pharmaceuticals, Inc.2003-11-11Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralDispensing Solutions, Inc.2012-12-12Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralLife Line Home Care Services, Inc.2012-02-29Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralSandoz Inc2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release10 mg/1OralCitron Pharma LLC2015-08-19Not applicableUs
OmeprazoleCapsule, delayed release40 mg/1OralUnit Dose Services2009-01-21Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralBlenheim Pharmacal, Inc.2015-03-10Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralPreferred Pharmaceuticals, Inc.2013-11-18Not applicableUs
Omeprazole DrCapsule, delayed release20 mg/1OralDIRECT RX2015-01-01Not applicableUs
Omeprazole DrCapsule, delayed release40 mg/1OralDIRECT RX2015-01-01Not applicableUs
Omeprazole DrCapsule, delayed release20 mg/1OralNorthwind Pharmaceuticals, LLC2014-10-27Not applicableUs
Approved Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ahi-omeprazoleTablet, delayed release20 mgOralAccord Healthcare IncNot applicableNot applicableCanada
Being Well OmeprazoleTablet, delayed release20 mg/1OralSave A Lot Food Stores Ltd2008-03-20Not applicableUs
Berkley and Jensen OmeprazoleTablet, delayed release20 mg/1OralBJWC2008-02-28Not applicableUs
Care One OmeprazoleTablet, delayed release20 mg/1OralAmerican Sales Company2008-02-29Not applicableUs
Core Values OmeprazoleTablet, delayed release20 mg/1OralHarmon Stores Inc.2016-11-22Not applicableUs
Dg Health OmeprazoleTablet, delayed release20 mg/1OralDolgencorp, LLC2010-02-14Not applicableUs
Equaline OmeprazoleTablet, delayed release20 mg/1OralSupervalu Inc2008-02-22Not applicableUs
Equate OmeprazoleCapsule, delayed release20 mg/1OralWal Mart Stores Inc2015-09-02Not applicableUs
Equate Omeprazole Delayed Release Acid ReducerTablet, delayed release20 mg/1OralWal Mart Stores Inc2008-02-27Not applicableUs
Exchange Select OmeprazoleTablet, delayed release20 mg/1OralArmy & Air Force Exchange Service2008-10-28Not applicableUs
Family Wellness OmeprazoleTablet, delayed release20 mg/1OralFamily Dollar Services Inc2013-08-14Not applicableUs
Formu Care OmeprazoleTablet, delayed release20 mg/1OralAccess Business Group LLC2009-07-08Not applicableUs
Fulton Street Market OmeprazoleTablet, delayed release20 mg/1OralAccess Business Group LLC2009-07-08Not applicableUs
GenozolTablet, delayed release20 mg/1OralGenomma Lab Usa, Inc.2016-07-29Not applicableUs
Good Neighbor Pharmacy OmeprazoleCapsule, delayed release20 mg/1OralAmerisource Bergen2015-03-25Not applicableUs
Good Neighbor Pharmacy OmeprazoleTablet, delayed release20 mg/1OralAmerisource Bergen2008-02-27Not applicableUs
Good Sense OmeprazoleTablet, delayed release20 mg/1OralL. Perrigo Company2008-02-28Not applicableUs
Harmon Face Values OmeprazoleTablet, delayed release20 mg/1OralHarmon Stores Inc.2011-12-18Not applicableUs
Harris Teeter OmeprazoleTablet, delayed release20 mg/1OralHarris Teeter, LLC2015-03-30Not applicableUs
Health Mart OmeprazoleTablet, delayed release20 mg/1OralMc Kesson2012-03-20Not applicableUs
Healthy Accents OmeprazoleTablet, delayed release20 mg/1OralDZA Brands LLC2008-03-03Not applicableUs
Heartburn ControlCapsule, delayed release20 mgOralApotex Inc2015-03-12Not applicableCanada
Kirkland Signature OmeprazoleTablet, delayed release20 mg/1OralCostco Wholesale Company2008-02-27Not applicableUs
Leader OmeprazoleTablet, delayed release20 mg/1OralREMEDYREPACK INC.2016-07-07Not applicableUs
Leader OmeprazoleTablet, delayed release20 mg/1OralCardinal Health2008-02-28Not applicableUs
Members Mark OmeprazoleTablet, delayed release20 mg/1OralSam's West Inc2008-02-25Not applicableUs
Novo-omeprazoleTablet, delayed release20 mgOralTeva Canada LimitedNot applicableNot applicableCanada
OlexTablet, delayed release20 mgOralPendopharm Division Of De Pharmascience Inc2014-09-17Not applicableCanada
OmepCapsule, delayed release20 mgOralSandoz Canada Incorporated2015-11-25Not applicableCanada
OmeprazoleTablet, delayed release20 mg/1OralPublix Super Markets Inc2008-05-12Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralSafeway2008-02-25Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralRite Aid Corporation2015-03-26Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralCVS Pharmacy2008-02-29Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralShopko Stores Operating Co., LLC2015-12-02Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralWalgreen Company2008-02-27Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralH E B2015-04-03Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralWestern Family Foods Inc2008-02-28Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralHy Vee Inc2008-03-02Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralCVS Pharmacy2015-03-27Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralRite Aid Corporation2008-02-25Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralShopko Stores Operating Co., LLC2013-06-05Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralMajor Pharmaceuticals2008-02-29Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralGericare Pharmaceuticals2008-08-30Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralH E B2008-02-29Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralPerrigo New York Inc2008-02-25Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralWalgreen Company2015-03-25Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralKroger Company2008-02-25Not applicableUs
OmeprazoleCapsule, delayed release20 mg/1OralMeijer Distribution Inc2015-03-25Not applicableUs
OmeprazoleTablet, delayed release20 mg/1OralPhysicians Total Care, Inc.2008-06-19Not applicableUs
OmeprazoleTablet, delayed release20 mgOralPharmascience Inc2015-10-08Not applicableCanada
OmeprazoleTablet, delayed release20 mgOralLaboratoire Riva Inc2015-11-16Not applicableCanada
OmeprazoleTablet, delayed release20 mg/1OralMeijer Distribution Inc2008-02-29Not applicableUs
Omeprazole 20 mgTablet, delayed release20 mgOralTeva Canada LimitedNot applicableNot applicableCanada
Omeprazole Delayed ReleaseTablet, delayed release20 mg/1OralDexcel Ltd.2008-03-01Not applicableUs
Omeprazole Delayed ReleaseTablet, delayed release20 mg/1OralWeeks & Leo Co., Inc.2011-07-12Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralHEB2015-07-01Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralWal Mart Stores Inc2010-01-15Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralAlbertsons Companies2016-02-01Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20.6 mg/1OralGericare Pharmaceuticals2013-04-01Not applicableUs
Omeprazole MagnesiumCapsule20.6 mg/1OralBi Mart2015-11-25Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralKaiser Permanente2011-05-21Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralChain Drug Marketing Association2012-12-11Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralThe Kroger Co.2014-03-17Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralTarget Corporation2011-05-19Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralMeijer Distribution Inc2014-09-22Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralChain Drug Consortium, LLC2013-11-26Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralCvs Health Corp.2011-11-01Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralFreds2015-10-16Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralThe Kroger Co.2015-03-12Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralWalgreens Company2015-09-01Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralFreds2015-10-16Not applicableUs
Omeprazole MagnesiumCapsule, delayed release20 mg/1OralDr. Reddy's Laboratories Limited2009-11-12Not applicableUs
OmesecCapsule, delayed release20 mg/1OralCorporacion Infarmasa2010-02-28Not applicableUs
Preferred Plus OmeprazoleTablet, delayed release20 mg/1OralKinray2014-10-20Not applicableUs
Prilosec OtcTablet, delayed release20.6 mg/1OralA S Medication Solutions2003-07-14Not applicableUs
Prilosec OtcTablet, delayed release20.6 mg/1OralThe Procter & Gamble Manufacturing Company2003-07-14Not applicableUs
Prilosec OtcTablet, delayed release20 mg/1OralThe Procter & Gamble Manufacturing Company2012-08-15Not applicableUs
Prilosec OtcTablet, delayed release20.6 mg/1OralPhysicians Total Care, Inc.2005-05-23Not applicableUs
Quality Choice OmeprazoleTablet, delayed release20 mg/1OralChain Drug Marketing Association2014-03-01Not applicableUs
Shoprite OmeprazoleTablet, delayed release20 mg/1OralWakefern Food Corporation2013-08-06Not applicableUs
Signature Care OmeprazoleTablet, delayed release20 mg/1OralSafeway2015-09-18Not applicableUs
Simply Right OmeprazoleTablet, delayed release20 mg/1OralSam's West Inc2011-12-28Not applicableUs
Smart Sense OmeprazoleTablet, delayed release20 mg/1OralKmart Corporation2011-01-20Not applicableUs
Sound Body OmeprazoleTablet, delayed release20 mg/1OralBig Lots Stores, Inc.2015-08-17Not applicableUs
Sunmark OmeprazoleTablet, delayed release20 mg/1OralMc Kesson2008-02-26Not applicableUs
Topcare OmeprazoleTablet, delayed release20 mg/1OralTopco Associates LLC2008-02-29Not applicableUs
Topcare Omeprazole Delayed ReleaseCapsule, delayed release20 mg/1OralTopco Associates LLC2016-02-02Not applicableUs
Up and Up OmeprazoleCapsule, delayed release20 mg/1OralTarget Corporation2015-04-17Not applicableUs
Up and Up OmeprazoleTablet, delayed release20 mg/1OralTarget Corporation2009-07-14Not applicableUs
Unapproved/Other Products Not Available
International Brands
NameCompany
AntraNot Available
AudazolNot Available
BelmazolNot Available
CeprandalNot Available
DanloxNot Available
DesecNot Available
ElgamNot Available
EmeprotonNot Available
GasecNot Available
GastrimutNot Available
GastrolocNot Available
IndurganNot Available
InhibitronNot Available
LogastricNot Available
LosecNot Available
MepralNot Available
MopralNot Available
OlexinNot Available
OmaprenNot Available
OmepralNot Available
OmeprazonNot Available
OmeprolNot Available
OmezolNot Available
OmisecNot Available
OmizacNot Available
OrtanolNot Available
ParizacNot Available
PrazidecNot Available
PrazolitNot Available
ProcelacNot Available
RamezolNot Available
RegulacidNot Available
SanamidolNot Available
UlceralNot Available
UlcesepNot Available
UltopNot Available
ZepralNot Available
Brand mixtures
NameLabellerIngredients
Omeclamox-pakPernix Therapeutics, LLC
Omeprazole and Sodium BicarbonateOceanside Pharmaceuticals
Omeprazole and Sodium BicrabonateDr.Reddy's Laboratories Limited
Omeprazole/sodium BicarbonatePrasco Laboratories
YospralaAralez Pharmaceuticals Us Inc.
ZegeridPhysicians Total Care, Inc.
Zegerid OtcBayer Health Care Llc
Salts
Name/CASStructureProperties
Omeprazole magnesium
Thumb
  • InChI Key: KWORUUGOSLYAGD-UHFFFAOYNA-N
  • Monoisotopic Mass: 712.198816192
  • Average Mass: 713.121
DBSALT000131
Omeprazole sodium
ThumbNot applicableDBSALT000857
Categories
UNIIKG60484QX9
CAS number73590-58-6
WeightAverage: 345.416
Monoisotopic: 345.114712179
Chemical FormulaC17H19N3O3S
InChI KeySUBDBMMJDZJVOS-UHFFFAOYSA-N
InChI
InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)
IUPAC Name
6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole
SMILES
COC1=CC2=C(C=C1)N=C(N2)S(=O)CC1=NC=C(C)C(OC)=C1C
Pharmacology
IndicationOmeprazole is indicated for the treatment of duodenal ulcers, benign gastric ulcers, gastroesophageal reflux disease (GERD), heartburn and other symptoms associated with GERD, erosive esophagitis, and long-term treatment of pathological hypersecretory conditions like Zollinger-Ellison syndrome, multiple endocrine adenomas, and systemic mastocytosis.
Structured Indications
PharmacodynamicsAfter oral administration, the onset of the anti-secretory effect of omeprazole occurs within one hour and maximum effect occurring within two hours. At 24 hours, inhibition of secretion is approximately 50% of maximum and duration of inhibition lasts up to 72 hours. Although omeprazole has a very short plasma half-life, the anti-secretory effect lasts for a long time due to prolonged binding to parietal H+/K+ ATPase enzyme. When the drug has been discontinued, secretory activity will return to baseline over 3-5 days. The inhibitory effect of omeprazole on acid secretion increases with repeated once-daily dosing, reaching a plateau after four days. In studies involving more than 200 patients, serum gastrin levels increased during the first 1 to 2 weeks of once-daily administration of therapeutic doses of omeprazole in parallel with inhibition of acid secretion. Systemic effects of omeprazole in the CNS, cardiovascular and respiratory systems have not been found to date.
Mechanism of actionOmeprazole is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of the H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, omeprazole blocks the final step in acid production, thus reducing gastric acidity.
TargetKindPharmacological actionActionsOrganismUniProt ID
Potassium-transporting ATPase alpha chain 1Proteinyes
inhibitor
HumanP20648 details
Related Articles
AbsorptionThe delayed-release capsule are enteric-coated (as omeprazole is acid-labile) so the absorption of omprazole begins once the granules leave the stomach. Absorption is rapid. Peak plasma levels occur within 0.5 - 3.5 hours. The absolute bioavailability (compared with intravenous administration) of the delayed-release capsule is 30-40% at doses of 20 - 40 mg, due to presystemic metabolism. This value increases slightly when given repeatedly. Based on a relative bioavailability study, the AUC and Cmax of PRILOSEC (omeprazole magnesium) for Delayed-Release Oral Suspension were 87% and 88% of those for PRILOSEC Delayed-Release Capsules, respectively. Interestingly, when the 40 mg delayed release capsule is given with or without applesauce, it is bioequivalent. However, when the 20 mg delayed release capsule is given with the same conditions, it is not bioequivalent. When the same capsule is given to the elderly, bioavailability increases. Omeprazole was 76% bioavailable.
Volume of distributionNot Available
Protein binding95% bound to human plasma protein.
Metabolism

Hepatic. Omeprazole is extensively metabolized by the cytochrome P450 (CYP) enzyme system. The two primary CYP isozymes involved are CYP2C19 and CYP3A4. Metabolism is stereoselective in which the S-isomer is converted to 5'O-desmethylomeprazole via CYP2C19. CYP3A4 converts the S-isomer to 3-hydroxyomeprazole. The R-isomer is converted to 5-hydroxyomeprazole by CYP2C19. CYP3A4 converts the R-isomer to any four different metabolites: 5-hydroxyomeprazole (5-OH OME), omeprazole sulfone (OME sulfone), 5'-O-desmethylomeprazole (5'-desmethyl OME), and 3-hydroxyomeprazole (3-OH OME).

SubstrateEnzymesProduct
Omeprazole
5-HydroxyomeprazoleDetails
Omeprazole
5'-O-Desmethyl omeprazoleDetails
Omeprazole
Omeprazole sulfoneDetails
Omeprazole
3-HydroxyomeprazoleDetails
Route of eliminationUrinary excretion is a primary route of excretion of omeprazole metabolites. Little, if any unchanged drug was excreted in the urine. The majority of the dose (about 77%) was eliminated in urine as at least six metabolites. Two were identified as hydroxyomeprazole and the corresponding carboxylic acid. The remainder of the dose was recovered in the feces.
Half life0.5-1 hour (healthy subjects, delayed-release capsule); 3 hours (hepatic impairment)
Clearance
  • 500 – 600 mL/min [Total body clearance, healthy subjects, delayed-release capsule]
  • 250 mL/min [Plasma clearance, Geriatric]
  • 70 mL/min [Plasma clearance, Hepatic Impairment]
ToxicitySymptoms of overdose include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, headache, and dry mouth.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Omeprazole Action PathwayDrug actionSMP00226
Omeprazole Metabolism PathwayDrug metabolismSMP00613
SNP Mediated Effects
Interacting Gene/EnzymeSNP RS IDAllele nameDefining changeEffectReference(s)
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4244285 CYP2C19*2A Allele, homozygotePoor metabolizer, lower dose requirement, improved drug efficacy9867757
Cytochrome P450 2C19
Gene symbol: CYP2C19
UniProt: P33261
rs4986893 CYP2C19*3A Allele, homozygotePoor metabolizer, lower dose requirement, improved drug efficacy9867757
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
AbirateroneThe serum concentration of Omeprazole can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Omeprazole.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Omeprazole.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Omeprazole.Approved
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Omeprazole.Approved
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Omeprazole.Approved, Vet Approved
AdinazolamThe metabolism of Adinazolam can be decreased when combined with Omeprazole.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Omeprazole.Approved
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Omeprazole.Experimental
Alendronic acidThe therapeutic efficacy of Alendronic acid can be decreased when used in combination with Omeprazole.Approved
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Omeprazole.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Omeprazole.Approved, Investigational
AlosetronThe metabolism of Alosetron can be decreased when combined with Omeprazole.Approved, Withdrawn
AlprazolamThe metabolism of Alprazolam can be decreased when combined with Omeprazole.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Omeprazole.Approved, Investigational
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Omeprazole.Approved, Withdrawn
AmiodaroneThe metabolism of Omeprazole can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Omeprazole.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Omeprazole.Approved, Vet Approved
AmphetamineOmeprazole can cause an increase in the absorption of Amphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Omeprazole.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Omeprazole.Approved
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Omeprazole.Approved
AprepitantThe serum concentration of Omeprazole can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Omeprazole.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Omeprazole.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Omeprazole.Approved, Investigational
ArmodafinilThe metabolism of Omeprazole can be decreased when combined with Armodafinil.Approved, Investigational
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Omeprazole.Approved, Investigational
ArtemetherThe metabolism of Artemether can be decreased when combined with Omeprazole.Approved
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Omeprazole.Approved, Investigational
AtenololThe serum concentration of Atenolol can be increased when it is combined with Omeprazole.Approved
AtomoxetineThe metabolism of Omeprazole can be decreased when combined with Atomoxetine.Approved
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Omeprazole.Approved, Investigational
AzelastineThe metabolism of Azelastine can be decreased when combined with Omeprazole.Approved
AzithromycinThe metabolism of Omeprazole can be decreased when combined with Azithromycin.Approved
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Omeprazole.Approved
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Omeprazole.Approved, Vet Approved
BexaroteneThe serum concentration of Omeprazole can be decreased when it is combined with Bexarotene.Approved, Investigational
BoceprevirThe metabolism of Omeprazole can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Omeprazole can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Omeprazole.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Omeprazole.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Omeprazole.Approved
BromazepamThe metabolism of Bromazepam can be decreased when combined with Omeprazole.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Omeprazole.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Omeprazole.Approved
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Omeprazole.Approved, Investigational
BuprenorphineThe metabolism of Buprenorphine can be decreased when combined with Omeprazole.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Omeprazole.Approved
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Omeprazole.Approved
CabozantinibThe metabolism of Cabozantinib can be decreased when combined with Omeprazole.Approved
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Omeprazole.Approved
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Omeprazole.Experimental
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Omeprazole.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Omeprazole.Approved
CapecitabineThe metabolism of Omeprazole can be decreased when combined with Capecitabine.Approved, Investigational
CarbamazepineThe metabolism of Omeprazole can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe metabolism of Carbinoxamine can be decreased when combined with Omeprazole.Approved
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Omeprazole.Approved
CarisoprodolThe metabolism of Carisoprodol can be decreased when combined with Omeprazole.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Omeprazole.Approved, Investigational
CefditorenThe serum concentration of Cefditoren can be decreased when it is combined with Omeprazole.Approved
CelecoxibThe metabolism of Celecoxib can be decreased when combined with Omeprazole.Approved, Investigational
CeritinibThe serum concentration of Omeprazole can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Omeprazole.Withdrawn
ChloramphenicolThe metabolism of Omeprazole can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Omeprazole.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Omeprazole.Approved
CholecalciferolThe metabolism of Omeprazole can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Omeprazole.Approved
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Omeprazole.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Omeprazole.Approved
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Omeprazole.Approved, Investigational
CisaprideThe metabolism of Cisapride can be decreased when combined with Omeprazole.Approved, Investigational, Withdrawn
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Omeprazole.Approved
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Omeprazole.Approved
ClarithromycinThe metabolism of Omeprazole can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Omeprazole can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Omeprazole.Approved, Illicit
ClodronateThe therapeutic efficacy of Clodronate can be decreased when used in combination with Omeprazole.Approved, Investigational, Vet Approved
clomethiazoleThe metabolism of clomethiazole can be decreased when combined with Omeprazole.Investigational
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Omeprazole.Approved, Investigational
ClomipramineThe metabolism of Clomipramine can be decreased when combined with Omeprazole.Approved, Vet Approved
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Omeprazole.Approved
ClopidogrelOmeprazole may decrease the antiplatelet activities of Clopidogrel.Approved, Nutraceutical
ClotiazepamThe metabolism of Clotiazepam can be decreased when combined with Omeprazole.Approved, Illicit
ClotrimazoleThe metabolism of Omeprazole can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Omeprazole.Approved
CobicistatThe metabolism of Omeprazole can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Omeprazole.Approved
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Omeprazole.Approved
ConivaptanThe serum concentration of Omeprazole can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Omeprazole.Approved
CrizotinibThe metabolism of Omeprazole can be decreased when combined with Crizotinib.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Omeprazole.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
CyclosporineThe metabolism of Omeprazole can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Omeprazole can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
CysteamineThe therapeutic efficacy of Cysteamine can be decreased when used in combination with Omeprazole.Approved, Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Omeprazole.Approved
DabrafenibThe serum concentration of Omeprazole can be decreased when it is combined with Dabrafenib.Approved
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Omeprazole.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Omeprazole.Approved
DapsoneThe metabolism of Dapsone can be decreased when combined with Omeprazole.Approved, Investigational
DarunavirThe metabolism of Omeprazole can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Dasatinib can be decreased when it is combined with Omeprazole.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Omeprazole.Approved
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Omeprazole.Approved
DeferasiroxThe serum concentration of Omeprazole can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Delavirdine can be decreased when it is combined with Omeprazole.Approved
DesipramineThe metabolism of Desipramine can be decreased when combined with Omeprazole.Approved
DexamethasoneThe serum concentration of Omeprazole can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexmethylphenidateOmeprazole can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved
DextroamphetamineOmeprazole can cause an increase in the absorption of Dextroamphetamine resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Omeprazole.Approved
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Omeprazole.Approved, Illicit, Vet Approved
DiclofenacThe metabolism of Diclofenac can be decreased when combined with Omeprazole.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Omeprazole.Approved
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Omeprazole.Approved
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Omeprazole.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Omeprazole.Approved
DihydroergotamineThe metabolism of Omeprazole can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Omeprazole.Illicit
DiltiazemThe metabolism of Omeprazole can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Diphenhydramine can be decreased when combined with Omeprazole.Approved
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Omeprazole.Approved
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Omeprazole.Approved, Investigational
DolasetronThe metabolism of Dolasetron can be decreased when combined with Omeprazole.Approved
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Omeprazole.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Omeprazole.Approved
DorzolamideThe metabolism of Dorzolamide can be decreased when combined with Omeprazole.Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Omeprazole.Approved
DoxepinThe metabolism of Doxepin can be decreased when combined with Omeprazole.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Omeprazole.Approved, Investigational
DoxycyclineThe metabolism of Omeprazole can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Dronabinol can be increased when it is combined with Omeprazole.Approved, Illicit
DronedaroneThe metabolism of Omeprazole can be decreased when combined with Dronedarone.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Omeprazole.Approved
EfavirenzThe serum concentration of Omeprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Omeprazole.Approved, Investigational
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Omeprazole.Approved, Investigational
EnzalutamideThe serum concentration of Omeprazole can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Omeprazole.Approved, Investigational
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Omeprazole.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Omeprazole.Approved, Investigational
ErythromycinThe metabolism of Omeprazole can be decreased when combined with Erythromycin.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be increased when it is combined with Omeprazole.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Omeprazole can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe metabolism of Esomeprazole can be decreased when combined with Omeprazole.Approved, Investigational
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estriol can be increased when it is combined with Omeprazole.Approved, Vet Approved
EstroneThe serum concentration of Estrone can be increased when it is combined with Omeprazole.Approved
EszopicloneThe metabolism of Eszopiclone can be decreased when combined with Omeprazole.Approved
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Omeprazole.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Omeprazole.Withdrawn
Etidronic acidThe therapeutic efficacy of Etidronic acid can be decreased when used in combination with Omeprazole.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Omeprazole.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Omeprazole.Approved, Investigational
EtravirineThe serum concentration of Omeprazole can be decreased when it is combined with Etravirine.Approved
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Omeprazole.Approved
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Omeprazole.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Omeprazole.Approved
FelodipineThe metabolism of Omeprazole can be decreased when combined with Felodipine.Approved, Investigational
Ferric CarboxymaltoseOmeprazole can cause a decrease in the absorption of Ferric Carboxymaltose resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric CitrateOmeprazole can cause a decrease in the absorption of Ferric Citrate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Ferric pyrophosphateOmeprazole can cause a decrease in the absorption of Ferric pyrophosphate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Omeprazole.Approved
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Omeprazole.Approved
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Omeprazole.Approved
FloxuridineThe metabolism of Omeprazole can be decreased when combined with Floxuridine.Approved
FluconazoleThe serum concentration of Omeprazole can be increased when it is combined with Fluconazole.Approved
FluindioneThe serum concentration of Fluindione can be increased when it is combined with Omeprazole.Investigational
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Omeprazole.Approved
FlunitrazepamThe metabolism of Flunitrazepam can be decreased when combined with Omeprazole.Approved, Illicit
FluorouracilThe metabolism of Omeprazole can be decreased when combined with Fluorouracil.Approved
FluoxetineThe metabolism of Fluoxetine can be decreased when combined with Omeprazole.Approved, Vet Approved
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Omeprazole.Approved, Investigational
FlutamideThe metabolism of Flutamide can be decreased when combined with Omeprazole.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Omeprazole.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Omeprazole.Approved
FluvoxamineThe metabolism of Omeprazole can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Omeprazole.Approved, Investigational
FosamprenavirThe metabolism of Omeprazole can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Omeprazole can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Fosphenytoin can be increased when it is combined with Omeprazole.Approved
Fusidic AcidThe serum concentration of Omeprazole can be increased when it is combined with Fusidic Acid.Approved
GavestinelThe metabolism of Gavestinel can be decreased when combined with Omeprazole.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Omeprazole.Approved, Investigational
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Omeprazole.Approved
GemfibrozilThe metabolism of Omeprazole can be decreased when combined with Gemfibrozil.Approved
GliclazideThe metabolism of Gliclazide can be decreased when combined with Omeprazole.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Omeprazole.Approved
GlipizideThe metabolism of Glipizide can be decreased when combined with Omeprazole.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Omeprazole.Approved
GlyburideThe metabolism of Glyburide can be decreased when combined with Omeprazole.Approved
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Omeprazole.Approved
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Omeprazole.Withdrawn
GuanfacineThe metabolism of Guanfacine can be decreased when combined with Omeprazole.Approved, Investigational
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Omeprazole.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Omeprazole.Approved, Vet Approved
HexobarbitalThe metabolism of Hexobarbital can be decreased when combined with Omeprazole.Approved
Histamine PhosphateThe metabolism of Histamine Phosphate can be decreased when combined with Omeprazole.Approved
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Omeprazole.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Omeprazole.Approved, Illicit
IbandronateThe therapeutic efficacy of Ibandronate can be decreased when used in combination with Omeprazole.Approved, Investigational
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Omeprazole.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Omeprazole.Approved
IdelalisibThe serum concentration of Omeprazole can be increased when it is combined with Idelalisib.Approved
IfosfamideThe metabolism of Ifosfamide can be decreased when combined with Omeprazole.Approved
ImatinibThe metabolism of Omeprazole can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Omeprazole.Approved
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Omeprazole.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Omeprazole.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Omeprazole.Investigational
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Omeprazole.Approved, Investigational
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Omeprazole.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Omeprazole.Approved, Investigational
IronOmeprazole can cause a decrease in the absorption of Iron resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Iron DextranOmeprazole can cause a decrease in the absorption of Iron Dextran resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Vet Approved
Iron saccharateOmeprazole can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
IsavuconazoniumThe metabolism of Omeprazole can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Omeprazole can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Omeprazole can be decreased when combined with Isradipine.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Omeprazole.Approved, Investigational
IvacaftorThe serum concentration of Omeprazole can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Omeprazole.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Omeprazole.Approved
KetamineThe metabolism of Ketamine can be decreased when combined with Omeprazole.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Omeprazole.Approved
KetobemidoneThe metabolism of Ketobemidone can be decreased when combined with Omeprazole.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Omeprazole.Approved, Investigational
KetoconazoleThe metabolism of Omeprazole can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Omeprazole.Approved, Vet Approved
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Omeprazole.Approved, Investigational
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Omeprazole.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Omeprazole.Approved, Investigational
LapatinibThe metabolism of Lapatinib can be decreased when combined with Omeprazole.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be decreased when it is combined with Omeprazole.Approved
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Omeprazole.Approved, Investigational
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Omeprazole.Approved
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Omeprazole.Approved
LesinuradThe metabolism of Lesinurad can be decreased when combined with Omeprazole.Approved
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Omeprazole.Approved, Investigational
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Omeprazole.Approved, Investigational
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Omeprazole.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Omeprazole.Investigational
LidocaineThe metabolism of Omeprazole can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Omeprazole.Approved
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Omeprazole.Approved
LopinavirThe metabolism of Omeprazole can be decreased when combined with Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Omeprazole.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Omeprazole.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Omeprazole.Approved
LosartanThe serum concentration of Losartan can be increased when it is combined with Omeprazole.Approved
LovastatinThe metabolism of Omeprazole can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Omeprazole can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Omeprazole can be increased when it is combined with Lumacaftor.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Omeprazole.Approved, Investigational
MacitentanThe metabolism of Macitentan can be decreased when combined with Omeprazole.Approved
MannitolThe serum concentration of Mannitol can be increased when it is combined with Omeprazole.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Omeprazole.Approved
MelatoninThe metabolism of Melatonin can be decreased when combined with Omeprazole.Approved, Nutraceutical, Vet Approved
MeloxicamThe metabolism of Meloxicam can be decreased when combined with Omeprazole.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Omeprazole.Investigational, Withdrawn
MeprobamateThe metabolism of Meprobamate can be decreased when combined with Omeprazole.Approved, Illicit
MesalazineThe therapeutic efficacy of Mesalazine can be decreased when used in combination with Omeprazole.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Omeprazole.Approved
MethadoneThe metabolism of Methadone can be decreased when combined with Omeprazole.Approved
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Omeprazole.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Omeprazole.Approved, Vet Approved
MethsuximideThe metabolism of Methsuximide can be decreased when combined with Omeprazole.Approved
MethylphenidateOmeprazole can cause an increase in the absorption of Methylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects.Approved, Investigational
MethylphenobarbitalThe metabolism of Methylphenobarbital can be decreased when combined with Omeprazole.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Omeprazole.Approved, Vet Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Omeprazole.Approved, Investigational
MetronidazoleThe metabolism of Metronidazole can be decreased when combined with Omeprazole.Approved
MexiletineThe metabolism of Omeprazole can be decreased when combined with Mexiletine.Approved
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Omeprazole.Approved, Illicit
MifepristoneThe serum concentration of Omeprazole can be increased when it is combined with Mifepristone.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Omeprazole.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Omeprazole.Approved
MitotaneThe serum concentration of Omeprazole can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Omeprazole.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Omeprazole.Approved
ModafinilThe serum concentration of Omeprazole can be decreased when it is combined with Modafinil.Approved, Investigational
MontelukastThe metabolism of Montelukast can be decreased when combined with Omeprazole.Approved
MorphineThe serum concentration of Morphine can be increased when it is combined with Omeprazole.Approved, Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Omeprazole.Approved, Investigational
Mycophenolic acidThe serum concentration of Mycophenolic acid can be decreased when it is combined with Omeprazole.Approved
NadololThe serum concentration of Nadolol can be increased when it is combined with Omeprazole.Approved
NafcillinThe serum concentration of Omeprazole can be decreased when it is combined with Nafcillin.Approved
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Omeprazole.Approved
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Omeprazole.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Omeprazole.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Omeprazole.Approved, Investigational
NefazodoneThe metabolism of Omeprazole can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of the active metabolites of Nelfinavir can be reduced when Nelfinavir is used in combination with Omeprazole resulting in a loss in efficacy.Approved
NetupitantThe serum concentration of Omeprazole can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Omeprazole can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Omeprazole can be decreased when combined with Nicardipine.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Omeprazole.Approved, Vet Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Omeprazole.Approved
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Omeprazole.Approved
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Omeprazole.Approved, Investigational
NilutamideThe metabolism of Nilutamide can be decreased when combined with Omeprazole.Approved
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Omeprazole.Approved
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Omeprazole.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Omeprazole.Approved
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Omeprazole.Approved, Investigational
OlaparibThe metabolism of Omeprazole can be decreased when combined with Olaparib.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Omeprazole.Approved
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Omeprazole.Approved
OndansetronThe metabolism of Ondansetron can be decreased when combined with Omeprazole.Approved
OsimertinibThe serum concentration of Omeprazole can be increased when it is combined with Osimertinib.Approved
OspemifeneThe metabolism of Ospemifene can be decreased when combined with Omeprazole.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Omeprazole.Approved
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Omeprazole.Approved
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Omeprazole.Approved, Vet Approved
PalbociclibThe serum concentration of Omeprazole can be increased when it is combined with Palbociclib.Approved
PamidronateThe therapeutic efficacy of Pamidronate can be decreased when used in combination with Omeprazole.Approved
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Omeprazole.Approved, Investigational
PantoprazoleThe metabolism of Omeprazole can be decreased when combined with Pantoprazole.Approved
ParamethadioneThe metabolism of Paramethadione can be decreased when combined with Omeprazole.Approved
ParecoxibThe metabolism of Parecoxib can be decreased when combined with Omeprazole.Approved
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Omeprazole.Approved
Peginterferon alfa-2bThe serum concentration of Omeprazole can be increased when it is combined with Peginterferon alfa-2b.Approved
PentamidineThe metabolism of Pentamidine can be decreased when combined with Omeprazole.Approved
PentobarbitalThe metabolism of Omeprazole can be increased when combined with Pentobarbital.Approved, Vet Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Omeprazole.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Omeprazole.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Omeprazole.Withdrawn
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Omeprazole.Approved
PhenobarbitalThe metabolism of Omeprazole can be increased when combined with Phenobarbital.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Omeprazole.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Omeprazole.Approved, Vet Approved
PhenytoinThe serum concentration of Omeprazole can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PioglitazoneThe metabolism of Pioglitazone can be decreased when combined with Omeprazole.Approved, Investigational
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Omeprazole.Approved
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Omeprazole.Approved, Investigational
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Omeprazole.Approved
PodofiloxThe metabolism of Podofilox can be decreased when combined with Omeprazole.Approved
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Omeprazole.Approved
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Omeprazole.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
PrasugrelThe metabolism of Prasugrel can be decreased when combined with Omeprazole.Approved
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Omeprazole.Approved
PraziquantelThe metabolism of Praziquantel can be decreased when combined with Omeprazole.Approved, Vet Approved
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Omeprazole.Approved
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Omeprazole.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Omeprazole.Approved, Vet Approved
PrimidoneThe metabolism of Omeprazole can be increased when combined with Primidone.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Omeprazole.Approved, Vet Approved
ProguanilThe metabolism of Proguanil can be decreased when combined with Omeprazole.Approved
PromazineThe metabolism of Promazine can be decreased when combined with Omeprazole.Approved, Vet Approved
PropofolThe metabolism of Propofol can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Propranolol can be increased when it is combined with Omeprazole.Approved, Investigational
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Omeprazole.Approved
PyrimethamineThe metabolism of Omeprazole can be decreased when combined with Pyrimethamine.Approved, Vet Approved
QuazepamThe metabolism of Quazepam can be decreased when combined with Omeprazole.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be increased when it is combined with Omeprazole.Approved
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Omeprazole.Approved
QuinineThe serum concentration of Quinine can be increased when it is combined with Omeprazole.Approved
RabeprazoleThe metabolism of Rabeprazole can be decreased when combined with Omeprazole.Approved, Investigational
RaltegravirThe serum concentration of Raltegravir can be increased when it is combined with Omeprazole.Approved
RamelteonThe metabolism of Ramelteon can be decreased when combined with Omeprazole.Approved, Investigational
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Omeprazole.Approved
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Omeprazole.Approved, Investigational
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Omeprazole.Approved
RifabutinThe metabolism of Omeprazole can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Omeprazole can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Omeprazole can be increased when combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Omeprazole.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Omeprazole.Approved
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Omeprazole.Approved
RisedronateThe therapeutic efficacy of Risedronate can be decreased when used in combination with Omeprazole.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Omeprazole.Approved, Investigational
RitonavirThe metabolism of Omeprazole can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Omeprazole.Approved
RofecoxibThe metabolism of Rofecoxib can be decreased when combined with Omeprazole.Investigational, Withdrawn
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Omeprazole.Approved, Investigational
RopiniroleThe metabolism of Omeprazole can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Omeprazole.Approved, Investigational
RosuvastatinThe metabolism of Rosuvastatin can be decreased when combined with Omeprazole.Approved
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Omeprazole.Approved, Vet Approved
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Omeprazole.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Omeprazole.Approved
SecobarbitalThe metabolism of Omeprazole can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe metabolism of Selegiline can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Omeprazole.Approved
SeratrodastThe metabolism of Seratrodast can be decreased when combined with Omeprazole.Approved, Investigational
SertralineThe metabolism of Sertraline can be decreased when combined with Omeprazole.Approved
SildenafilThe metabolism of Omeprazole can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Omeprazole.Approved
SiltuximabThe serum concentration of Omeprazole can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Omeprazole can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Omeprazole.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Omeprazole.Approved, Investigational, Withdrawn
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Omeprazole.Approved
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Omeprazole.Approved, Investigational
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Omeprazole.Approved
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Omeprazole.Experimental
St. John's WortThe serum concentration of Omeprazole can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Omeprazole can be increased when it is combined with Stiripentol.Approved
SulfadiazineThe metabolism of Omeprazole can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfamethoxazoleThe metabolism of Sulfamethoxazole can be decreased when combined with Omeprazole.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Omeprazole.Approved
SulfinpyrazoneThe metabolism of Sulfinpyrazone can be decreased when combined with Omeprazole.Approved
SulfisoxazoleThe metabolism of Omeprazole can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SuprofenThe metabolism of Suprofen can be decreased when combined with Omeprazole.Approved, Withdrawn
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Omeprazole.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Omeprazole.Approved
TapentadolThe metabolism of Tapentadol can be decreased when combined with Omeprazole.Approved
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Omeprazole.Experimental
Technetium tc 99m etidronateThe therapeutic efficacy of Technetium tc 99m etidronate can be decreased when used in combination with Omeprazole.Approved
Technetium Tc-99m MedronateThe therapeutic efficacy of Technetium Tc-99m Medronate can be decreased when used in combination with Omeprazole.Approved
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Omeprazole.Approved
TelaprevirThe metabolism of Omeprazole can be decreased when combined with Telaprevir.Approved
TelithromycinThe metabolism of Omeprazole can be decreased when combined with Telithromycin.Approved
TemazepamThe metabolism of Temazepam can be decreased when combined with Omeprazole.Approved
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Omeprazole.Approved
TeniposideThe metabolism of Teniposide can be decreased when combined with Omeprazole.Approved
TenofovirThe metabolism of Omeprazole can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Omeprazole.Approved
TerbinafineThe metabolism of Terbinafine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Omeprazole.Withdrawn
TeriflunomideThe serum concentration of Omeprazole can be decreased when it is combined with Teriflunomide.Approved
TestosteroneThe metabolism of Testosterone can be decreased when combined with Omeprazole.Approved, Investigational
ThalidomideThe metabolism of Thalidomide can be decreased when combined with Omeprazole.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Omeprazole can be decreased when combined with Theophylline.Approved
ThiamylalThe metabolism of Thiamylal can be decreased when combined with Omeprazole.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Omeprazole.Approved
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Omeprazole.Approved
TiclopidineThe metabolism of Omeprazole can be decreased when combined with Ticlopidine.Approved
TiludronateThe therapeutic efficacy of Tiludronate can be decreased when used in combination with Omeprazole.Approved, Vet Approved
TimololThe serum concentration of Timolol can be increased when it is combined with Omeprazole.Approved
TipranavirThe serum concentration of Omeprazole can be decreased when it is combined with Tipranavir.Approved, Investigational
TizanidineThe serum concentration of Tizanidine can be increased when it is combined with Omeprazole.Approved
TocilizumabThe serum concentration of Omeprazole can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe metabolism of Tofacitinib can be decreased when combined with Omeprazole.Approved, Investigational
TolbutamideThe metabolism of Omeprazole can be decreased when combined with Tolbutamide.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Omeprazole.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Omeprazole.Approved
TopiramateThe metabolism of Omeprazole can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Omeprazole.Approved, Investigational
TorasemideThe metabolism of Torasemide can be decreased when combined with Omeprazole.Approved
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Omeprazole.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Omeprazole.Approved, Investigational
TranylcypromineThe metabolism of Omeprazole can be decreased when combined with Tranylcypromine.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Omeprazole.Approved
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Omeprazole.Approved, Investigational
TretinoinThe metabolism of Tretinoin can be decreased when combined with Omeprazole.Approved, Investigational, Nutraceutical
TrimethadioneThe metabolism of Trimethadione can be decreased when combined with Omeprazole.Approved
TrimethoprimThe metabolism of Trimethoprim can be decreased when combined with Omeprazole.Approved, Vet Approved
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Omeprazole.Approved
TroglitazoneThe metabolism of Troglitazone can be decreased when combined with Omeprazole.Withdrawn
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Omeprazole.Approved
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Omeprazole.Approved
ValdecoxibThe metabolism of Valdecoxib can be decreased when combined with Omeprazole.Investigational, Withdrawn
Valproic AcidThe metabolism of Valproic Acid can be decreased when combined with Omeprazole.Approved, Investigational
ValsartanThe metabolism of Omeprazole can be decreased when combined with Valsartan.Approved, Investigational
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Omeprazole.Approved
VemurafenibThe serum concentration of Omeprazole can be increased when it is combined with Vemurafenib.Approved
VenetoclaxThe serum concentration of Venetoclax can be increased when it is combined with Omeprazole.Approved
VenlafaxineThe metabolism of Omeprazole can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Omeprazole can be decreased when combined with Verapamil.Approved
VicrivirocThe metabolism of Vicriviroc can be decreased when combined with Omeprazole.Investigational
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Omeprazole.Approved
VincristineThe serum concentration of Vincristine can be increased when it is combined with Omeprazole.Approved, Investigational
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Omeprazole.Approved
VoriconazoleThe serum concentration of Omeprazole can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Omeprazole.Approved
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Omeprazole.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Omeprazole.Approved, Investigational, Withdrawn
ZafirlukastThe metabolism of Zafirlukast can be decreased when combined with Omeprazole.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Omeprazole.Approved
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Omeprazole.Approved
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Omeprazole.Approved
ZileutonThe metabolism of Zileuton can be decreased when combined with Omeprazole.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Omeprazole can be decreased when combined with Ziprasidone.Approved
Zoledronic acidThe therapeutic efficacy of Zoledronic acid can be decreased when used in combination with Omeprazole.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Omeprazole.Approved
ZopicloneThe metabolism of Zopiclone can be decreased when combined with Omeprazole.Approved
Food Interactions
  • Avoid alcohol.
  • Take 30-60 minutes before meals.
References
Synthesis Reference

Arne E. Brandstrom, Bo R. Lamm, “Processes for the preparation of omeprazole and intermediates therefore.” U.S. Patent US4620008, issued October, 1982.

US4620008
General References
  1. Yang YX, Lewis JD, Epstein S, Metz DC: Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006 Dec 27;296(24):2947-53. [PubMed:17190895 ]
External Links
ATC CodesA02BC01A02BD05A02BD01
AHFS Codes
  • 56:28.36
PDB EntriesNot Available
FDA labelDownload (218 KB)
MSDSDownload (73.8 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9968
Blood Brain Barrier-0.6326
Caco-2 permeable+0.8867
P-glycoprotein substrateNon-substrate0.5573
P-glycoprotein inhibitor IInhibitor0.6622
P-glycoprotein inhibitor IINon-inhibitor0.968
Renal organic cation transporterNon-inhibitor0.542
CYP450 2C9 substrateNon-substrate0.7838
CYP450 2D6 substrateSubstrate0.6175
CYP450 3A4 substrateSubstrate0.6901
CYP450 1A2 substrateInhibitor0.7505
CYP450 2C9 inhibitorNon-inhibitor0.907
CYP450 2D6 inhibitorNon-inhibitor0.9231
CYP450 2C19 inhibitorInhibitor0.8994
CYP450 3A4 inhibitorInhibitor0.796
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7895
Ames testNon AMES toxic0.5692
CarcinogenicityNon-carcinogens0.8318
BiodegradationNot ready biodegradable0.9778
Rat acute toxicity2.2254 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.719
hERG inhibition (predictor II)Non-inhibitor0.8977
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Apotex inc
  • Dr reddys laboratories ltd
  • Impax laboratories inc
  • Kremers urban development co
  • Lek pharmaceuticals d d
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Watson laboratories inc florida
  • Astrazeneca lp
  • Dexcel pharma technologies ltd
  • Santarus, Inc.
Packagers
Dosage forms
FormRouteStrength
Capsule, delayed releaseOral20 mg
Tablet, delayed releaseOral20 mg/1
Tablet, delayed releaseOral10 mg
Tablet, delayed releaseOral20 mg
Capsule, delayed releaseOral40 mg
Kit
CapsuleOral10 mg/1
CapsuleOral40 mg/1
Capsule, delayed releaseOral10 mg/1
Capsule, delayed releaseOral40 mg/1
Capsule, delayed release pelletsOral10 mg/1
Capsule, delayed release pelletsOral20 mg/1
Capsule, delayed release pelletsOral40 mg/1
Capsule, gelatin coatedOral
Powder, for suspensionOral
CapsuleOral20.6 mg/1
Capsule, delayed releaseOral20 mg/1
Capsule, delayed releaseOral20.6 mg/1
CapsuleOral20 mg/1
Granule, delayed releaseOral10 mg/1
Granule, delayed releaseOral2.5 mg/1
Tablet, delayed releaseOral20.6 mg/1
Capsule, delayed releaseOral10 mg
Tablet, film coatedOral
CapsuleOral
Prices
Unit descriptionCostUnit
PriLOSEC 30 20 mg Delayed Release Capsule Bottle459.99USD bottle
Zegerid 30 20-1680 mg Packets Packet224.27USD packet
Zegerid 30 40-1680 mg Packets Packet224.27USD packet
PriLOSEC 30 10 mg Delayed Release Capsule Bottle174.37USD bottle
Omeprazole 28 20 mg Enteric Coated Tabs Box25.99USD box
PriLOSEC OTC 14 20 mg Enteric Coated Tabs Box19.99USD box
PriLOSEC 40 mg Delayed Release Capsule9.59USD capsule
Prilosec dr 40 mg capsule9.22USD capsule
Omeprazole 40 mg Delayed Release Capsule7.69USD capsule
Zegerid 40-1100 mg capsule7.48USD capsule
Zegerid 20 mg capsule7.19USD capsule
Zegerid 40 mg capsule6.46USD capsule
Prilosec dr 20 mg capsule6.24USD capsule
Prilosec 20 mg capsule dr6.15USD capsule
Prilosec dr 10 mg capsule5.59USD capsule
Omeprazole powder5.05USD g
Omeprazole 20 mg Delayed Release Capsule4.32USD capsule
Omeprazole 10 mg Delayed Release Capsule3.13USD capsule
Losec (Sustained-Release Tablet) 20 mg Capsule/Sustained Release Tablet2.48USD tablet
Losec (Sustained-Release Tablet) 10 mg Capsule/Sustained Release Tablet1.97USD tablet
Losec (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.24USD tablet
Apo-Omeprazole 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Mylan-Omeprazole 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Pms-Omeprazole (Delayed Release Tablet) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Pms-Omeprazole (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Ratio-Omeprazole (Sustained-Release Tablet) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Sandoz Omeprazole (Sustained-Release Capsule) 20 mg Capsule/Sustained Release Tablet1.15USD tablet
Mylan-Omeprazole 10 mg Capsule/Sustained Release Tablet0.86USD tablet
Sandoz Omeprazole (Sustained-Release Capsule) 10 mg Capsule/Sustained Release Tablet0.86USD tablet
Zegerid otc 20-1100 mg capsule0.78USD capsule
Prilosec otc 20 mg tablet0.76USD tablet
Omeprazole dr 20 mg tablet0.66USD tablet
CVS Pharmacy omeprazole dr 20 mg tablet0.53USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA1338377 No1996-06-112013-06-11Canada
CA2180535 No2004-03-232014-01-05Canada
US5690960 No1994-11-252014-11-25Us
US5817338 No1995-10-062015-10-06Us
US5840737 No1996-07-152016-07-15Us
US5900424 No1996-05-042016-05-04Us
US6147103 Yes1999-04-092019-04-09Us
US6150380 Yes1999-05-102019-05-10Us
US6166213 Yes1999-04-092019-04-09Us
US6191148 Yes1999-04-092019-04-09Us
US6403616 No1999-11-152019-11-15Us
US6428810 No1999-11-032019-11-03Us
US6489346 No1996-07-162016-07-16Us
US6645988 No1996-07-162016-07-16Us
US6699885 No1996-07-162016-07-16Us
US6780882 No1996-07-152016-07-15Us
US7399772 No1996-07-152016-07-15Us
US9023391 No2005-08-162025-08-16Us
USRE45198 No1996-07-162016-07-16Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point155 °CFDA label
water solubilityVery slightly soluble FDA label
logP2.23SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.359 mg/mLALOGPS
logP1.66ALOGPS
logP2.43ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)9.29ChemAxon
pKa (Strongest Basic)4.77ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area77.1 Å2ChemAxon
Rotatable Bond Count5ChemAxon
Refractivity93.66 m3·mol-1ChemAxon
Polarizability37.45 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
1D NMR1H NMR SpectrumNot Available
2D NMR[1H,13C] 2D NMR SpectrumNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfinylbenzimidazoles. These are polycyclic aromatic compounds containing a sulfinyl group attached at the position 2 of a benzimidazole moiety.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzimidazoles
Sub ClassSulfinylbenzimidazoles
Direct ParentSulfinylbenzimidazoles
Alternative Parents
Substituents
  • Sulfinylbenzimidazole
  • Anisole
  • Methylpyridine
  • Alkyl aryl ether
  • Benzenoid
  • Pyridine
  • Heteroaromatic compound
  • Imidazole
  • Azole
  • Sulfoxide
  • Azacycle
  • Sulfinyl compound
  • Ether
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Sodium:potassium-exchanging atpase activity
Specific Function:
Catalyzes the hydrolysis of ATP coupled with the exchange of H(+) and K(+) ions across the plasma membrane. Responsible for acid production in the stomach.
Gene Name:
ATP4A
Uniprot ID:
P20648
Molecular Weight:
114117.74 Da
References
  1. Tajima A, Koizumi K, Suzuki K, Higashi N, Takahashi M, Shimada T, Terano A, Hiraishi H, Kuwayama H: Proton pump inhibitors and recurrent bleeding in peptic ulcer disease. J Gastroenterol Hepatol. 2008 Dec;23 Suppl 2:S237-41. doi: 10.1111/j.1440-1746.2008.05557.x. [PubMed:19120905 ]
  2. Shi S, Klotz U: Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008 Oct;64(10):935-51. doi: 10.1007/s00228-008-0538-y. Epub 2008 Aug 5. [PubMed:18679668 ]
  3. Kirchheiner J, Glatt S, Fuhr U, Klotz U, Meineke I, Seufferlein T, Brockmoller J: Relative potency of proton-pump inhibitors-comparison of effects on intragastric pH. Eur J Clin Pharmacol. 2009 Jan;65(1):19-31. doi: 10.1007/s00228-008-0576-5. Epub 2008 Oct 17. [PubMed:18925391 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Foti RS, Wahlstrom JL: CYP2C19 inhibition: the impact of substrate probe selection on in vitro inhibition profiles. Drug Metab Dispos. 2008 Mar;36(3):523-8. Epub 2007 Nov 29. [PubMed:18048485 ]
  2. Li XQ, Andersson TB, Ahlstrom M, Weidolf L: Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos. 2004 Aug;32(8):821-7. [PubMed:15258107 ]
  3. Li XQ, Weidolf L, Simonsson R, Andersson TB: Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther. 2005 Nov;315(2):777-87. Epub 2005 Aug 10. [PubMed:16093273 ]
  4. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  5. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  6. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T: Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther. 1997 Nov;283(2):434-42. [PubMed:9353355 ]
  7. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Li XQ, Weidolf L, Simonsson R, Andersson TB: Enantiomer/enantiomer interactions between the S- and R- isomers of omeprazole in human cytochrome P450 enzymes: major role of CYP2C19 and CYP3A4. J Pharmacol Exp Ther. 2005 Nov;315(2):777-87. Epub 2005 Aug 10. [PubMed:16093273 ]
  2. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  3. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. [PubMed:8423765 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Turpeinen M, Uusitalo J, Jalonen J, Pelkonen O: Multiple P450 substrates in a single run: rapid and comprehensive in vitro interaction assay. Eur J Pharm Sci. 2005 Jan;24(1):123-32. [PubMed:15626586 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP2C18
Uniprot ID:
P33260
Molecular Weight:
55710.075 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, nad(p)h as one donor, and incorporation of one atom of oxygen
Specific Function:
Catalyzes the side-chain cleavage reaction of cholesterol to pregnenolone.
Gene Name:
CYP11A1
Uniprot ID:
P05108
Molecular Weight:
60101.87 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Vitamin d 24-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics.
Gene Name:
CYP1A1
Uniprot ID:
P04798
Molecular Weight:
58164.815 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Oxygen binding
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, retinoid and xenobiotics. Preferentially oxidizes 17beta-estradiol to the carcinogenic 4-hydroxy derivative, and a variety of procarcinogenic compou...
Gene Name:
CYP1B1
Uniprot ID:
Q16678
Molecular Weight:
60845.33 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Organic anion transmembrane transporter activity
Specific Function:
May act as an inducible transporter in the biliary and intestinal excretion of organic anions. Acts as an alternative route for the export of bile acids and glucuronides from cholestatic hepatocytes (By similarity).
Gene Name:
ABCC3
Uniprot ID:
O15438
Molecular Weight:
169341.14 Da
References
  1. Hitzl M, Klein K, Zanger UM, Fritz P, Nussler AK, Neuhaus P, Fromm MF: Influence of omeprazole on multidrug resistance protein 3 expression in human liver. J Pharmacol Exp Ther. 2003 Feb;304(2):524-30. [PubMed:12538803 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Pauli-Magnus C, Rekersbrink S, Klotz U, Fromm MF: Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2001 Dec;364(6):551-7. [PubMed:11770010 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both from mitochondria to cytosol and from cytosol to extracellular space, and cellular export of hemin, and heme. Xenobiotic transporter that may play an important role in the exclusion of xenobiotics from t...
Gene Name:
ABCG2
Uniprot ID:
Q9UNQ0
Molecular Weight:
72313.47 Da
References
  1. Breedveld P, Zelcer N, Pluim D, Sonmezer O, Tibben MM, Beijnen JH, Schinkel AH, van Tellingen O, Borst P, Schellens JH: Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions. Cancer Res. 2004 Aug 15;64(16):5804-11. [PubMed:15313923 ]
  2. Suzuki K, Doki K, Homma M, Tamaki H, Hori S, Ohtani H, Sawada Y, Kohda Y: Co-administration of proton pump inhibitors delays elimination of plasma methotrexate in high-dose methotrexate therapy. Br J Clin Pharmacol. 2009 Jan;67(1):44-9. doi: 10.1111/j.1365-2125.2008.03303.x. Epub 2008 Nov 17. [PubMed:19076159 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:54